Claims
- 1. A compound of the structural formula: ##STR4## in which: R is a lower straight chain alkyl of 1-6 carbons;
- R.sub.1 is hydrogen, lower alkyl of 1-5 carbons or lower alkenyl of 3-5 carbons;
- R.sub.2 and R.sub.3 are hydrogen or lower alkanoyl of 2-5 carbons; and
- R.sub.4 is hydrogen or one or two substituents from the group consisting of trifluoromethyl, halo, methyl, methoxy, alkanoyloxy of 2-5 carbons, hydroxy or methylthio; or pharmaceutically acceptable acid addition salts thereof.
- 2. A compound of claim 1 having dopaminergic activity in which:
- R.sub.1 is hydrogen or methyl;
- R.sub.2 and R.sub.3 are hydrogen; and
- R.sub.4 is hydrogen or p-hydroxy.
- 3. A compound of claim 1 in which R is methyl.
- 4. A compound of claim 1 being 6-methyl-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine or one of its pharmaceutically acceptable acid addition salts.
- 5. The compound of claim 4 in the form of its methylsulfonate salt.
- 6. The compound of claim 4 in the form of its hydrochloride salt.
- 7. A compound of claim 1 being 3,6-dimethyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine or one of its pharmaceutically acceptable acid addition salts.
- 8. A compound of claim 1 being 6-propyl-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine or one of its pharmaceutically acceptable acid addition salts.
- 9. A pharmaceutical composition having dopaminergic activity comprising a pharmaceutically effective quantity of a compound of claims 1, 2, 3, 4, 5, 6, 7 or 8 combined with a pharmaceutical carrier adapted for oral or injectable administration.
- 10. A method of producing dopaminergic activity in a subject in need thereof comprising administering orally or parenterally to said subject an amount of a compound of claims 1, 2, 3, 4, 5, 6, 7 or 8 which is effective therefore.
- 11. The method of claim 1 in which the compound is 6-methyl-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine or one of its pharmaceutically acceptable acid addition salts and the subject is in need of antihypertensive therapy.
Parent Case Info
This application is a continuation-in-part of our copending application, Ser. No. 903,325 filed May 5, 1978, abandoned which is in turn a continuation-in-part of Ser. No. 852,404 filed Nov. 17, 1977, now U.S. 4,165,372 issued Aug. 28, 1979.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3483185 |
Tokolics et al. |
Dec 1969 |
|
3496166 |
Mull et al. |
Feb 1970 |
|
Non-Patent Literature Citations (1)
Entry |
Gilman, H. Org. Chem. vol. I pp. 433-434 (1938). |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
903325 |
May 1978 |
|
Parent |
852404 |
Nov 1977 |
|